A BILL 
To require the guidance of the Food and Drug Administra-
tion on reducing the risk of human immunodeficiency 
virus (HIV), hepatitis A, and hepatitis B transmission 
by blood and blood products (including the donor history 
questionnaire) to be based on an individual risk assess-
ment of sexual behaviors upon which all donors are eval-
uated equally, without regard to sexual orientation or 
gender identity, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
23:48 Sep 05, 2020
H8168
2 
•HR 8168 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Science in Blood Dona-
2
tion Act of 2020’’. 
3
SEC. 2. REQUIRING GUIDANCE ON REDUCING RISK OF HIV, 
4
HEPATITIS A, AND HEPATITIS B TRANS-
5
MISSION BY BLOOD PRODUCTS TO BE BASED 
6
ON AN INDIVIDUAL RISK ASSESSMENT. 
7
(a) IN GENERAL.—The Secretary of Health and 
8
Human Services acting through the Commissioner of Food 
9
and Drugs (in this section referred to as the ‘‘Secretary’’) 
10
shall— 
11
(1) not later than 45 days after the date of en-
12
actment of this Act, revise and publish the guidance 
13
of the Food and Drug Administration on reducing 
14
the risk of human immunodeficiency virus, hepatitis 
15
A, and hepatitis B transmission by blood and blood 
16
products so as to eliminate— 
17
(A) the recommendation to defer for 3 
18
months from the most recent sexual contact, a 
19
man who has had sex with another man during 
20
the past 3 months; and 
21
(B) the recommendation to defer for 3 
22
months from the most recent sexual contact, a 
23
female who has had sex during the past 3 
24
months with a man who has had sex with an-
25
other man in the past 3 months; 
26
23:48 Sep 05, 2020
H8168
3 
•HR 8168 IH
(2) not later than 45 days after the date of en-
1
actment of this Act, initiate a process— 
2
(A) to update such guidance— 
3
(i) in conformity with paragraph (1); 
4
and 
5
(ii) so as to ensure that such guid-
6
ance, including the corresponding donor 
7
deferral recommendations, are based on an 
8
individual risk assessment of sexual behav-
9
iors upon which all donors are evaluated 
10
equally, without regard to sexual orienta-
11
tion or gender identity; and 
12
(B) to update the donor history question-
13
naire consistent with the updates under sub-
14
paragraph (A); and 
15
(3) not later than 18 months after the date of 
16
enactment of this Act— 
17
(A) complete the process initiated pursuant 
18
to paragraph (2); and 
19
(B) publish the updated guidance and 
20
donor history questionnaire. 
21
(b) SPECIAL RULE.—Throughout the period during 
22
which the Secretary is revising guidance pursuant to sub-
23
section (a)(1), the recommendations described in subpara-
24
23:48 Sep 05, 2020
H8168
4 
•HR 8168 IH
graphs (A) and (B) of subsections (a)(1) are deemed to 
1
be eliminated with respect to any individual who— 
2
(1) is a human subject in research; 
3
(2) is being routinely tested for human im-
4
munodeficiency virus, hepatitis A, and hepatitis B as 
5
part of such research; and 
6
(3) is not found, pursuant to such testing, to be 
7
positive for human immunodeficiency virus, hepatitis 
8
A, or hepatitis B. 
9
(c) PROGRESS REPORT.—The Secretary shall— 
10
(1) not later than each of 6 and 12 months 
11
after the date of enactment of this Act, submit a re-
12
port to the appropriate congressional committees on 
13
the progress made pursuant to the process under 
14
subsection (a)(2); and 
15
(2) not later than 18 months after the date of 
16
enactment of this Act, submit a final report to the 
17
appropriate congressional committees on the updated 
18
guidance and donor history questionnaire. 
19
Æ 
23:48 Sep 05, 2020
H8168
